Bruton’s tyrosine kinase inhibitors, TLR agonists, STAT3 inhibitors, and inhibitors of interleukin-1 receptor antagonists have also been shown to block BC progression by interfering with signaling pathways related to M2 phenotype polarization [220]. This evidence concerns the gene STAT3 and breast cancer.